Heparin-induced thrombocytopenia: Temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin

Chest

Volumn 122, Issue 1, 2002, Pages 37-42

  Lubenow, Norbert ^a   Kempf, Reiner ^a   Eichner, Angelika ^a   Eichler, Petra ^a   Carlsson, Lena E ^a   Greinacher, Andreas ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Heparin; Heparin induced thrombocytopenia; Platelets; Temporal pattern

Indexed keywords

HEPARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EXPOSURE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 0036301759     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.122.1.37     Document Type: Article

References (25)

1. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
2. Heparin-induced thrombocytopenia: Towards consensus
3. Heparin-induced thrombocytopenia
4. Diagnostic and therapeutic strategies of white clot syndrome
5. Clinical presentation of heparin-induced thrombocytopenia
6. Therapie der heparin-assoziierten thrombozytopenie
7. Heparin-induced thrombocytopenia: A clinicopathologic syndrome
8. Heparin-associated thrombocytopenia
9. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
10. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
11. First workshop for detection of heparin-induced antibodies: Validation of the heparin-induced platelet-activation test (HIPA) in comparison with a PF4/heparin ELISA
12. Clinical picture of heparin-induced thrombocytopenia
13. Heparin and low-molecular weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
14. Heparin-induced thrombocytopenia: Recommendations for optimal use of recombinant hirudin
15. Recombinant hirudin in clinical practice: Focus on lepirudin
16. Temporal aspects of heparin-induced thrombocytopenia
17. New treatment options for heparin-induced thrombocytopenia
18. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
19. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation
20. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery
21. Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: Successful reexposure to heparin
22. Cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia: Heparin reexposure and perioperative use of danaparoid, lepirudin and argatroban
23. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia